A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Drug Safety Testing Center Co., Ltd.

Drug Safety Testing Center Co., Ltd.

Table of Contents

Drug Safety Testing Center Co., Ltd. has been providing high-quality non-clinical services for over 40 years. This page will walk you through the key features of their non-clinical studies, examples of disease models, and available case studies. We hope you can use this information for a reference when selecting a contract research organization (CRO).

Features of Drug Safety Testing Center Co., Ltd.’s Non-Clinical Testing Services

Rapid Response Capability

The Center is committed to provide timely and attentive service in response to client requests. Data submission for sensitization and manual patch clamp tests is exceptionally fast. A dedicated support plan is also available for clients requesting the tests for the first time.

Strong Proposal Capability

The Center carefully addresses questions that may arise before or after a study—such as “What evaluation items are necessary?” or “What should be the next step after unexpected results?” Based on the characteristics of the test article and client target goals, the most suitable testing solution is proposed.

Reasonable Pricing

The Center believes that pricing is as important as quality. Its motto is to deliver high-quality data at reasonable costs without compromising scientific standards. By continuously seeking efficiency, the Center offers cost-effective services that maintain a strong balance between quality, delivery, and price.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Drug Safety Testing Center Co., Ltd.’s Disease Models

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

Rabbit Chymotrypsin-Induced High Intraocular Pressure Model

This rabbit model is used in ophthalmic pharmacology studies for glaucoma and retinal research. As a chronic glaucoma model capable of maintaining sustained high intraocular pressure, it is suitable for evaluating drugs targeting to lower intraocular pressure, treat glaucoma-related optic neuropathy, or address retinopathy.

Canine Dry Eye Model

This model is used as a corneal disease model in ophthalmic pharmacology studies. Dry eye conditions are reproduced by applying a controlled air flow to the canine cornea, causing corneal dryness. It is used for evaluating therapeutic agents for corneal epithelial damage and dry eye syndrome.

Rat Hydraulic Pressure-Induced Ischemia-Reperfusion Retinopathy Model

This rat model is also used for glaucoma and retina-related research. Retinopathy is reproduced by injecting saline into the anterior chamber and transiently applying an intraocular pressure of approximately 100 mmHg. It is used forevaluating drugs intended to treat or prevent retinopathy.

Drug Safety Testing Center Co., Ltd.’s Non-Clinical Case Study

No case studies are currently listed on the official website.

Company Information

For over 40 years, Drug Safety Testing Center Co., Ltd. has been providing reliable, high-quality non-clinical testing services for pharmaceuticals, quasi-drugs, and veterinary products.

Address	1-31-8 Takadanobaba, Shinjuku-ku, Tokyo
Tel	0493-54-3239
Website	https://www.dstc.jp/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us